Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by Zacks Investment Research to Sell

Milestone Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Milestone Pharmaceuticals Downgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by Zacks Investment Research to Sell